Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function

European Journal of Heart Failure

Volumn 20, Issue 5, 2018, Pages 910-919

  Hoes, Martijn F ^a   Grote Beverborg, Niels ^a   Kijlstra, J David ^a   Kuipers, Jeroen ^a   Swinkels, Dorine W ^b   Giepmans, Ben N G ^a   Rodenburg, Richard J ^b   van Veldhuisen, Dirk J ^a   de Boer, Rudolf A ^a   van der Meer, Peter ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Contractility; Heart failure; Human cardiomyocytes; Iron deficiency

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD71 ANTIGEN; DEFEROXAMINE; FERRITIN; IRON; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; SULFUR; TRANSFERRIN;

ARTICLE; CARDIAC MUSCLE CELL; CELL FUNCTION; CONTROLLED STUDY; DIASTOLE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ASSAY; GENE EXPRESSION; HEART MUSCLE CONTRACTILE FORCE; HUMAN; HUMAN CELL; HUMAN EMBRYONIC STEM CELL; INCUBATION TIME; IRON DEFICIENCY; IRON DEPLETION; MINERAL SUPPLEMENTATION; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL; SPECTROPHOTOMETRY; SYSTOLE; VIDEORECORDING; CELL CULTURE; COMPLICATION; HEART CONTRACTION; HEART FAILURE; HEART MITOCHONDRION; IRON DEFICIENCY ANEMIA; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANEMIA, IRON-DEFICIENCY; CELLS, CULTURED; HEART FAILURE; HUMANS; MITOCHONDRIA, HEART; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC;

EID: 85042531398     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.1154     Document Type: Article

References (34)

1. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:1872–1880.
2. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 2011;8:485–493.
3. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013;34:816–829.
4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
5. Comín-Colet J, Enjuanes C, González G, Torrens A, Cladellas M, Meroño O, Ribas N, Ruiz S, Gómez M, Verdú JM, Bruguera J. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail 2013;15:1164–1172.
6. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Lüscher TF, Mori C, Willenheimer R, Ponikowski P, Anker SD. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J 2013;34:30–38.
7. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013;165:575–582.e3.
8. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, von Haehling S, Doehner W, Banasiak W, Polonski L, Filippatos G, Anker SD, Ponikowski P. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 2011;17:899–906.
9. Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 2011;58:1241–1251.
10. Davies KJ, Maguire JJ, Brooks GA, Dallman PR, Packer L. Muscle mitochondrial bioenergetics, oxygen supply, and work capacity during dietary iron deficiency and repletion. Am J Physiol 1982;242:E418–E427.
11. Brunner-La Rocca HP, Crijns HJ. Iron i.v. in heart failure: ready for implementation? Eur Heart J 2015;36:645–647.
12. Núñez J, Monmeneu JV, Mollar A, Núñez E, Bodí V, Miñana G, García-Blas S, Santas E, Agüero J, Chorro FJ, Sanchis J, López-Lereu MP. Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study. ESC Heart Fail 2016;3:293–298.
13. Toblli JE, Di Gennaro F, Rivas C. Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron. Heart Lung Circ 2015;24:686–695.
14. Xu W, Barrientos T, Mao L, Rockman HA, Sauve AA, Andrews NC. Lethal cardiomyopathy in mice lacking transferrin receptor in the heart. Cell Rep 2015;13:533–545.
15. Lakhal-Littleton S, Wolna M, Chung YJ, Christian HC, Heather LC, Brescia M, Ball V, Diaz R, Santos A, Biggs D, Clarke K, Davies B, Robbins PA. An essential cell-autonomous role for hepcidin in cardiac iron homeostasis. Elife 2016;5:e19804.
16. Haddad S, Wang Y, Galy B, Korf-Klingebiel M, Hirsch V, Baru AM, Rostami F, Reboll MR, Heineke J, Flögel U, Groos S, Renner A, Toischer K, Zimmermann F, Engeli S, Jordan J, Bauersachs J, Hentze MW, Wollert KC, Kempf T. Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. Eur Heart J 2017;38:362–372.
17. Zhabyeyev P, Oudit GY. Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure. Eur Heart J 2017;38:373–375.
18. Lian X, Zhang J, Azarin SM, Zhu K, Hazeltine LB, Bao X, Hsiao C, Kamp TJ, Palecek SP. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat Protoc 2013;8:162–175.
19. Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert AD, Lan F, Diecke S, Huber B, Mordwinkin NM, Plews JR, Abilez OJ, Cui B, Gold JD, Wu JC. Chemically defined generation of human cardiomyocytes. Nat Methods 2014;11:855–860.
20. Smith RS. Iron excretion in thalassaemia major after administration of chelating agents. Br Med J 1962;2:1577–1580.
21. Hatcher HC, Singh RN, Torti FM, Torti SV. Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem 2009;1:1643–1670.
22. Cable H, Lloyd JB. Cellular uptake and release of two contrasting iron chelators. J Pharm Pharmacol 1999;51:131–134.
23. Khechaduri A, Bayeva M, Chang HC, Ardehali H. Heme levels are increased in human failing hearts. J Am Coll Cardiol 2013;61:1884–1893.
24. Rensvold JW, Ong SE, Jeevananthan A, Carr SA, Mootha VK, Pagliarini DJ. Complementary RNA and protein profiling identifies iron as a key regulator of mitochondrial biogenesis. Cell Rep 2013;3:237–245.
25. Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H, Pluhacek T, Spatenka J, Kovalcikova J, Drahota Z, Kautzner J, Pirk J, Houstek J. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. Eur J Heart Fail 2017;19:522–530.
26. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657–668.
27. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436–2448.
28. Qi Y, Dawson G. Hypoxia specifically and reversibly induces the synthesis of ferritin in oligodendrocytes and human oligodendrogliomas. J Neurochem 1994;63:1485–1490.
29. Qi Y, Jamindar TM, Dawson G. Hypoxia alters iron homeostasis and induces ferritin synthesis in oligodendrocytes. J Neurochem 1995;64:2458–2464.
30. Hanson ES, Leibold EA. Regulation of iron regulatory protein 1 during hypoxia and hypoxia/reoxygenation. J Biol Chem 1998;273:7588–7593.
31. Núñez J, Domínguez E, Ramón JM, Núñez E, Sanchis J, Santas E, Heredia R, González J, Miñana G, López L, Chorro FJ, Palau P. Iron deficiency and functional capacity in patients with advanced heart failure with preserved ejection fraction. Int J Cardiol 2016;207:365–367.
32. Jarvis JH, Jacobs A. Morphological abnormalities in lymphocyte mitochondria associated with iron-deficiency anaemia. J Clin Pathol 1974;27:973–979.
33. Seo YA, Li Y, Wessling-Resnick M. Iron depletion increases manganese uptake and potentiates apoptosis through ER stress. Neurotoxicology 2013;38:67–73.
34. Lee SJ, Zhang J, Choi AM, Kim HP. Mitochondrial dysfunction induces formation of lipid droplets as a generalized response to stress. Oxid Med Cell Longev 2013;2013:1–10.